Ads
related to: axsm stock target price
Search results
Mizuho Bolsters Price Target By 55% On This Migraine Stock
Benzinga via Yahoo Finance· 2 years agoMizuho Securities assumes coverage of Axsome Therapeutics Inc (NASDAQ: AXSM), with a Buy rating and...
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
Zacks via Yahoo Finance· 3 months agoAxsome Therapeutics, Inc. AXSM reported an adjusted loss of 73 cents per share for the fourth...
Analysts Just Made A Substantial Upgrade To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
Simply Wall St. via Yahoo Finance· 1 year agoAxsome Therapeutics, Inc. (NASDAQ:AXSM) shareholders will have a reason to smile today, with the...
Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges
Investor's Business Daily· 2 years agoRelmada Therapeutics stock crashed Thursday after its depression treatment failed a final-phase...
Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.
Investor's Business Daily· 1 year agoAxsome Therapeutics and BioXcel Therapeutics issued divergent earnings reports Monday. BTAI stock...
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its...
Simply Wall St. via Yahoo Finance· 2 years agoShareholders of Axsome Therapeutics, Inc. (NASDAQ:AXSM) will be pleased this week, given that the...
Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics AXSM announced that the first patient has been enrolled in the ADVANCE-2 phase...
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoAxsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company...
Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics’ AXSM shares have surged 118.4% in the past three months against the industry’s...
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
Zacks via Yahoo Finance· 2 years agoAxsome AXSM announced the enrollment of the first patient in the EMERGE phase III open label study...